Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - PubMed
6 hours ago
- #Long-term Efficacy
- #Atopic Dermatitis
- #Lebrikizumab
- Lebrikizumab demonstrated sustained efficacy up to 152 weeks in patients with moderate-to-severe atopic dermatitis from the ADjoin extension study.
- In responders at Week 16, high proportions maintained IGA 0/1 and EASI 75 responses: 84.0-94.1% from ADvocate studies and 86.7-94.9% from ADhere study.
- Safety profile remained consistent with prior studies, with most adverse events being mild or moderate, and low rates of serious events or discontinuations.